IRE-1α inhibitors
US9546149B2 · kind B2 · utility
2Cited by
131References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2015 |
| Grant date | Jan 17, 2017 |
| Priority date | — |
| Expiry date | Dec 15, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.